Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

Visit link:
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Leave a Reply